IMR Press / CEOG / Volume 45 / Issue 3 / DOI: 10.12891/ceog3896.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Intra-cervical misoprostol for the treatment of second-trimester fetal demise
Show Less
1 Department of Obstetrics and Gynecology, King Abdulaziz University, Jeddah, Saudi Arabia
Clin. Exp. Obstet. Gynecol. 2018, 45(3), 344–346;
Published: 10 June 2018

Purpose: Misoprostol has gained wide use in the treatment of reproductive disease. Previous applications have been administered through oral or vaginal routes. The efficacy of intra-cervical administration is not well studied. The authors report the outcome of intracervical administration of misoprostol in three women treated for termination of second-trimester fetal demise. Materials and Methods: Three women with second-trimester fetal demise were treated using 50 μg of misoprostol administered in the cervical os. Results: Complete abortion was observed by 17 hours, ten hours and 15 minutes, and seven hours and 35 minutes, respectively. Two women received oral non-steroidal anti-inflammatory drugs for mild abdominal pain and one woman received intramuscular opiates for moderate to severe abdominal pain. There were no adverse side effects or complications of treatment. Conclusions: Intra-cervical misoprostol was useful in the termination of second-trimester fetal demise. The dose required was much less than that used for oral or vaginal administration. Further studies are needed to confirm the present findings.
Back to top